Kymera Therapeutics reported positive results from its phase 1 healthy volunteer study using KT-621. Click here to find out why KYMR stock is a Strong Buy.

Kymera Therapeutics will announce Phase 1 trial results for KT-621 on June 2, 2025, via video webcast. Quiver AI Summary. Kymera Therapeutics, Inc. announced that it will release results from its ...